Advertisement

Annals of Hematology

, Volume 98, Issue 4, pp 1031–1032 | Cite as

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

  • Kenichi Makishima
  • Naoshi ObaraEmail author
  • Kantaro Ishitsuka
  • Shinichiro Sukegawa
  • Sakurako Suma
  • Yusuke Kiyoki
  • Naoko Baba
  • Tatsuhiro Sakamoto
  • Takayasu Kato
  • Manabu Kusakabe
  • Hidekazu Nishikii
  • Naoki Kurita
  • Yasuhisa Yokoyama
  • Mamiko Sakata-Yanagimoto
  • Yuichi Hasegawa
  • Shigeru Chiba
Letter to the Editor
  • 200 Downloads

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Written informed consent was obtained from the patient.

References

  1. 1.
    Berentsen S, Tjønnfjord GE (2012) Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 26:107–115.  https://doi.org/10.1016/j.blre.2012.01.002 CrossRefGoogle Scholar
  2. 2.
    Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sørbø JH, Tjønnfjord GE (2006) Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 91:460–466Google Scholar
  3. 3.
    Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Haukås E, Brudevold R, Sørbø JH, Næss IA, Malecka A, Tjønnfjord GE (2017) Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 130:537–541.  https://doi.org/10.1182/blood-2017-04-778175 CrossRefGoogle Scholar
  4. 4.
    Wong EK, Kavanagh D (2015) Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 165:306–320.  https://doi.org/10.1016/j.trsl.2014.10.010 CrossRefGoogle Scholar
  5. 5.
    Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE et al (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552–559.  https://doi.org/10.1056/NEJMoa031688 CrossRefGoogle Scholar
  6. 6.
    Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243.  https://doi.org/10.1056/NEJMoa061648 CrossRefGoogle Scholar
  7. 7.
    Shapiro R, Chin-Yee I, Lam S (2015) Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity. Clin Case Rep 3:942–944.  https://doi.org/10.1002/ccr3.399 CrossRefGoogle Scholar
  8. 8.
    Roth A, Hüttmann A, Rother RP, Dührsen U, Philipp T (2009) Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 113:3885–3886.  https://doi.org/10.1182/blood-2009-01-196329 CrossRefGoogle Scholar
  9. 9.
    Gupta N, Wang ES (2014) Long-term response of refractory primary cold aggulutinin disease to eculizumab therapy. Ann Hematol 93:343–344.  https://doi.org/10.1007/s00277-013-1800-7 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Kenichi Makishima
    • 1
  • Naoshi Obara
    • 1
    Email author
  • Kantaro Ishitsuka
    • 1
  • Shinichiro Sukegawa
    • 1
  • Sakurako Suma
    • 1
  • Yusuke Kiyoki
    • 1
  • Naoko Baba
    • 1
  • Tatsuhiro Sakamoto
    • 1
  • Takayasu Kato
    • 1
  • Manabu Kusakabe
    • 1
  • Hidekazu Nishikii
    • 1
  • Naoki Kurita
    • 1
  • Yasuhisa Yokoyama
    • 1
  • Mamiko Sakata-Yanagimoto
    • 1
  • Yuichi Hasegawa
    • 1
  • Shigeru Chiba
    • 1
  1. 1.Department of Hematology, Faculty of MedicineUniversity of TsukubaIbarakiJapan

Personalised recommendations